These findings indicate that tumor cell–derived FGFBP1–induced FAPα expression in HSCs could be an important regulatory mechanism for vessel co-option, and they also provide a potential therapeutic target to overcome CRCLM resistance to antiangiogenic therapy. Here, FAP is linked to neoplasm.